Blood-based monitoring of lung cancer patients
using cell-free DNA and VAR2-CTCs

Main funder

Funds granted by main funder (€)

  • 150 000,00

Funding program

Project timetable

Project start date: 15/12/2018

Project end date: 31/12/2021


In future oncology, options for cancer treatments are more diverse and costly, which increases the importance to study early response to therapies. Liquid biopsy, including inspection of cell-free DNA (cfDNA) and circulating tumor cells (CTCs), is a developing tool for personal monitoring of cancer, but the gut microbiome may affect the final success of the medication. Recently it was also found that a novel cancer binding VAR2CSA malaria protein retrieves CTCs much more efficiently than the traditional EpCAM marker, which may increase the value of CTCs when analysed together with cfDNA. To develop better cancer monitoring tools, we aim to make a longitudinal clinical sampling to study how size-selected cfDNA, VAR2-CTCs and gut microbiomes correlate together and provide early assessment of the expensive biological and immune-oncological treatments by lung cancer patients.

Principal Investigator

Primary responsible unit

Last updated on 2021-17-03 at 12:08